Cst CE 25/02 sda f 1/24 - Award of Specific Contract derived from the Dynamic Acquisition System for the Supply of the Exclusive Medicine REMDESIVIR 100 MG VIAL POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION for the Consorci Sanitari de Terrassa

This tender announces the award of a specific contract, designated CE 25/02 sda f 1/24, through the Dynamic Acquisition System (DAS). The contract is for the supply of the exclusive medicine REMDESIVIR, presented as a 100 mg vial of powder for concentrate for solution for infusion. The procuring entity is the Consorci Sanitari de Terrassa, a healthcare consortium serving the Terrassa region. Remdesivir is an antiviral medication, notably used in the treatment of COVID-19, indicating the critical nature of this supply. The use of the DAS facilitates a streamlined procurement process for essential and frequently required medical supplies. The award signifies that the Consorci Sanitari de Terrassa has successfully contracted a supplier to ensure the availability of Remdesivir for its healthcare facilities. This ensures that medical professionals have access to this important therapeutic agent for patient treatment, underscoring the consortium's commitment to maintaining a robust supply chain for critical medications and supporting public health initiatives within its jurisdiction.

This is a supplies contract in the health and medical services and general supplies sectors, with a focus on Pharmaceuticals. Located in Spain, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.